Koala retrovirus

Evaxion Announces Business Update and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 27, 2024
MSD, Conference, Innovation, Patient, Merck, Koala retrovirus, AI, Cancer, GHI, Merck & Co., Machine learning, European, Artificial intelligence

Closing of $5.3 million private placement on December 21, 2023, with participation of MSD Global Health Innovation Fund (MSD GHI), a corporate venture arm of Merck & Co., Inc., USA.

Key Points: 
  • Closing of $5.3 million private placement on December 21, 2023, with participation of MSD Global Health Innovation Fund (MSD GHI), a corporate venture arm of Merck & Co., Inc., USA.
  • MSD GHI is now the single largest shareholder in Evaxion, with ownership of around 15%.
  • COPENHAGEN, Denmark, March 27, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today provides a business update and announces full year 2023 financial results.
  • Evaxion hosted an R&D Day on March 19, 2024, providing deeper insights into the validated and differentiated AI-Immunology™ platform.

Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform

Retrieved on: 
Tuesday, March 19, 2024
MSD, EST, Koala retrovirus, Learning, AI, Neoplasm, Immune system, Machine learning, Vaccine, Collection, Medical device

The event will be hosted at our facilities in Hørsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. - 1.00 p.m. EST and can be accessed remotely here .

Key Points: 
  • The event will be hosted at our facilities in Hørsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. - 1.00 p.m. EST and can be accessed remotely here .
  • The R&D Day features a series of talks providing in-depth insights into Evaxion's clinically validated AI-Immunology™ platform for vaccine target discovery, design and development.
  • Christian Kanstrup, CEO of Evaxion, expresses enthusiasm: “We have been looking forward to this exciting day and welcome everyone interested in learning more about our technology and its potential for saving and improving lives.
  • We believe that we hold a truly differentiated position driven by our validated AI-Immunology™ platform and the multi-disciplinary capability set we have built around it.

Lupus Research Alliance 2023 Dr. William E. Paul Distinguished Innovator Award Granted to Yale School of Medicine Researcher Akiko Iwasaki, Ph.D.

Retrieved on: 
Tuesday, January 30, 2024
ERV, Yale school, Research, Lupus, Viral, DNA, Autoimmunity, Autoantibody, Tissue, DIA, Autoimmune disease, Iwasaki, Skin, Bacteria, SLE, LRA, Virus, Lupus Research Alliance, Inflammation, Genome, Doctor of Philosophy, Cell, Immune system, Koala retrovirus, Vaccine

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to grant the 2023 Dr. William E. Paul Distinguished Innovator Award (DIA) to Akiko Iwasaki, Ph.D., Sterling Professor of Immunobiology at the Yale School of Medicine. Dr. Iwasaki will investigate a possible cause of lupus – remnants of ancient viruses that have been integrated into our genome called endogenous retroviruses. The DIA provides investigators up to $1 million over four years to explore bold, paradigm-shifting ideas that could lead to groundbreaking discoveries in lupus research.

Key Points: 
  • NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The Lupus Research Alliance (LRA) is pleased to grant the 2023 Dr. William E. Paul Distinguished Innovator Award (DIA) to Akiko Iwasaki , Ph.D., Sterling Professor of Immunobiology at the Yale School of Medicine.
  • Dr. Iwasaki will investigate a possible cause of lupus – remnants of ancient viruses that have been integrated into our genome called endogenous retroviruses.
  • The DIA provides investigators up to $1 million over four years to explore bold, paradigm-shifting ideas that could lead to groundbreaking discoveries in lupus research.
  • With this award, we will probe the link between the immune system reacting to viruses within us as a possible trigger of lupus disease," commented Dr. Iwasaki.

Evaxion to Develop Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets

Retrieved on: 
Wednesday, January 24, 2024
ERV, Patient, American Society of Hematology, Cancer, Society, Koala retrovirus, Immunotherapy, Optimism, ASH

The new treatment opportunity may broaden the applicability of cancer vaccines.

Key Points: 
  • The new treatment opportunity may broaden the applicability of cancer vaccines.
  • Through the new vaccine targets, ERVs, treating patients unresponsive to conventional cancer immunotherapy may become possible.
  • With the elevated focus on this groundbreaking therapeutic concept, Evaxion has initiated preclinical activities with a goal of generating Proof-of-Concept data by the second half of 2024.
  • The ERV cancer vaccine targets represent a promising breakthrough that could significantly broaden the horizons of cancer vaccine applicability and marks a significant step forward in our commitment to improving healthcare through innovative and AI-powered approaches.

Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept

Retrieved on: 
Tuesday, November 28, 2023
Vaccine, Society, Artificial intelligence, ASH, Abstract, Cancer, Patient, Koala retrovirus, Bone marrow

Selected for an Oral Presentation – Evaxion has been chosen for an oral presentation from a competitive pool of >5000 submitted abstracts.

Key Points: 
  • Selected for an Oral Presentation – Evaxion has been chosen for an oral presentation from a competitive pool of >5000 submitted abstracts.
  • Based upon a novel source of targets, endogenous retroviruses (ERVs), combined with unique data insights, Evaxion has discovered a novel concept for precision vaccines in hematological malignancies and selected solid cancers.
  • Tailored Precision Vaccines – The precision vaccines are tailored to the specific tumor profiles and immune systems of patient groups.
  • The discovery will potentially allow for a broader than previously expected application of vaccines in cancer therapy.

Evaxion Announces Business Update and First Quarter 2023 Financial Results

Retrieved on: 
Wednesday, May 31, 2023
Vaccine, Exercise, DNA, AACR, European Medicines Agency, Survival, Infection, Cancer, CTA, CCL19, Immunotherapy, Messenger, Observational study, Erving Goffman, ASCO, Research and development, Development, Patient, Administration, Melanoma, Koala retrovirus, Research, Safety, Genome, Medical imaging, Pharmaceutical industry

“Evaxion continues to make significant progress towards our mission of advancing AI-powered immunotherapies to save lives,” said Per Norlén, Chief Executive Officer of Evaxion.

Key Points: 
  • “Evaxion continues to make significant progress towards our mission of advancing AI-powered immunotherapies to save lives,” said Per Norlén, Chief Executive Officer of Evaxion.
  • Operating spending for the first quarter of 2023 was offset by the proceeds from issue of shares and exercise of warrants.
  • Research and Development expenses were $3.9 million for the quarter ended March 31, 2023 as compared to $4.8 million for the quarter ended March 31, 2022.
  • General and Administrative expenses were $2.5 million for the quarter ended March 31, 2023 as compared to $1.6 million for the quarter ended March 31, 2022.

InProTher Announces EUR 6M Seed Financing with the Participation of the European Innovation Council Fund to Develop First-In-Class Cancer Immunotherapy

Retrieved on: 
Wednesday, May 24, 2023
Survival rate, Adenoviridae, European Innovation Council, Herv, Cancer, Venture capital financing, Breast, CMO, RNA, Immunotherapy, Doctor of Philosophy, HERV, Manager, EUR, Koala retrovirus, Novartis, MD, Investment, Immune system, Novo Nordisk Foundation, Drug development, FIH, Growth, Merck, BII, EIC, Seed, MPM, SME, Pharmaceutical industry, Management, Security (finance), EU

The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.

Key Points: 
  • The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.
  • InProTher has generated robust pre-clinical, proof-of-concept data that demonstrates therapeutic potential for multiple oncology indications including pancreatic, ovarian, breast and prostate cancer.
  • Jordi Naval, Chief Executive Officer of InProTher said: "InProTher is shifting the paradigm in cancer immunotherapy and is at an exciting phase of growth.
  • The Seed round of EUR 6M includes private investors and a convertible loan from EICF.

InProTher Announces EUR 6M Seed Financing with the Participation of the European Innovation Council Fund to Develop First-In-Class Cancer Immunotherapy

Retrieved on: 
Wednesday, May 24, 2023
Survival rate, Adenoviridae, European Innovation Council, Herv, Cancer, Venture capital financing, Breast, CMO, RNA, Immunotherapy, Doctor of Philosophy, HERV, Manager, EUR, Koala retrovirus, Novartis, MD, Investment, Immune system, Novo Nordisk Foundation, Drug development, FIH, Growth, Merck, BII, EIC, Seed, MPM, SME, Pharmaceutical industry, Management, Security (finance), EU

The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.

Key Points: 
  • The financing will enable InProTher to advance its lead drug candidate, IPT001, a first-in-class immunotherapy against solid tumors, into clinical development.
  • InProTher has generated robust pre-clinical, proof-of-concept data that demonstrates therapeutic potential for multiple oncology indications including pancreatic, ovarian, breast and prostate cancer.
  • Jordi Naval, Chief Executive Officer of InProTher said: "InProTher is shifting the paradigm in cancer immunotherapy and is at an exciting phase of growth.
  • The Seed round of EUR 6M includes private investors and a convertible loan from EICF.

Fourth quarter and full year 2022 financial results and business update

Retrieved on: 
Thursday, April 27, 2023
Antigen, Commercialization, AACR, ExpreS2ion Biotechnologies, University of Massachusetts, CPI, S. aureus, Neoplasm, Novel, European Medicines Agency, Aes, Cancer, CTA, Immunotherapy, EDT, Messenger, Sepsis, Erving Goffman, ASCO, Research and development, Development, American Society of Clinical Oncology, Patient, Administration, Data, Melanoma, CMV, Annual general meeting, Toxicology, Webcast, Koala retrovirus, PD-1, Research, Recurrence, IND, Society, NIH, Nivolumab, Pharmaceutical industry, Medical device, Cryptocurrency, Perfume, Vaccine

Technology advances: Novel ObsERV™ technology -- In March 2023, Evaxion reported the discovery of a novel new source of antigens for personalized cancer immunotherapy, based on endogenous retroviruses (ERVs). The AI-enabled technology has the potential to make “cold” tumors responsive to immunotherapy, which has the potential to broaden the patient population for immunotherapy significantly.

Key Points: 
  • Looking ahead to the rest of the year, we plan to report final Phase 1/2a results and interim Phase 2 data from the EVX-01 program in melanoma.
  • In addition, we intend to initiate recruitment in a Phase 1 study with EVX-03 in Q4 2023.
  • The Phase 2 study, initiated in September 2022, is expected to enroll up to 20 patients and report interim data in Q4 2023.
  • EVX-B2 (N. gonorrhoeae, preclinical) – In June 2022, Evaxion announced gonorrhea as a new bacterial vaccine candidate for N. gonorrhoeae.

Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients

Retrieved on: 
Tuesday, March 28, 2023
DNA, Clinical trial, Cancer, Immunotherapy, ERV-Fc, Patient, Koala retrovirus, EVX, ERV, Pharmaceutical industry

Recently, Evaxion announced that the Company has used its proprietary AI technology to discover a new treatment opportunity that may broaden cancer immunotherapy.

Key Points: 
  • Recently, Evaxion announced that the Company has used its proprietary AI technology to discover a new treatment opportunity that may broaden cancer immunotherapy.
  • Through new cancer targets, so-called ERVs (endogenous retroviruses), it may become possible to treat cancer patients who have until now been considered unresponsive to immunotherapy.
  • A natural next step is to maximize the value of our unique AI capabilities by focusing on target discovery and validation and early out-licensing opportunities.
  • In addition, the focus on our core will extend our cash runway towards the end of the year.”